The lab has been successful in gaining a slice of the joint-funded HRC/A*STAR cancer research initiative to promote collaboration between investigators in New Zealand and Singapore. The following is a summary of the funding published in the HRC and Otago press release.
YB-1 interacting partners in breast cancer progression
Principal Investigators: Professor Antony Braithwaite (Department of Pathology, University of Otago) and Professor Boon Huat Bay (National University of Singapore).
Project summary:Y-box binding protein 1 (YB-1) is commonly elevated in many human cancers. The cancer-promoting properties of YB-1 are associated with increased resistance to drugs, tumour growth and poor patient outcome. Control of these processes takes place in the nucleus. The precise molecular nature of the active cancer-promoting subtype of YB-1 present in the nucleus is unknown. Identification of this species will provide the basis for a specific and highly prognostic indicator. This proposal, which builds on our recently published analyses of endogenous YB-1, aims to identify the molecular nature of this cancer-promoting subtype of YB-1 and to determine how it functions. From this knowledge we will develop an antibody that specifically recognises only the nuclear YB-1 species and establish this species as a prognostic indicator for human cancers.
Congratulations to Antony Braithwaite and colleagues for gaining funding from the Health Research Council of New Zealand to study the role of p53 isoforms in cancer. Co-investigators on the grant are Noelyn Hung, Aaron Jeffs and Tania Slatter, all of the Department of Pathology.
Professor Antony Braithwaite
Department of Pathology, University of Otago, Tel (03) 479 7165
Can isoforms of the p53 tumour suppressor cause cancer?
36 months, $1,158,492